Home Archives 2012 September

Monthly Archives: September 2012

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations
Journal of Commercial Biotechnology
ADVERTISE HERE

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Simple flat-rate database subscription plans

Ultimate PlanPremium PlanBasic Plan
One year$1,995 Subscribe$1,795 Subscribe$1,095 Subscribe
One month$525 Subscribe$425 Subscribe$325 Subscribe
48 hours$95 Subscribe$75 Subscribe
Free Trial    Plan comparison    Site tour    Discount schedule    Contact

Drug Patent Expirations for August 14 2012

TradenameApplicantGeneric Name Patent Expiration
EXELONNovartisrivastigmineAug 14, 2012
EXELONNovartisrivastigmine tartrateAug 14, 2012

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

Drug Patent Expirations for September 2012

TradenameApplicantGeneric NamePatent NumberPatent Expiration
GEODONPfizer Incziprasidone hydrochloride5,312,925Sep 1, 2012
GEODONPfizerziprasidone hydrochloride5,312,925Sep 1, 2012
BESIVANCEBausch And Lombbesifloxacin hydrochloride5,447,926Sep 5, 2012
ALREXBausch And Lombloteprednol etabonate4,996,335*PEDSep 9, 2012
ZYLETBausch And Lombloteprednol etabonate; tobramycin4,996,335*PEDSep 9, 2012
LOTEMAXBausch And Lombloteprednol etabonate4,996,335*PEDSep 9, 2012
EMENDMerck And Co Incfosaprepitant dimeglumine7,214,692Sep 18, 2012
EMENDMerckaprepitant7,214,692Sep 18, 2012
EXFORGENovartisamlodipine besylate; valsartan5,399,578*PEDSep 21, 2012
DIOVANNovartisvalsartan5,399,578*PEDSep 21, 2012
LATISSEAllerganbimatoprost6,403,649Sep 21, 2012
EXFORGE HCTNovartisamlodipine besylate; hydrochlorothiazide; valsartan5,399,578*PEDSep 21, 2012
DIOVAN HCTNovartishydrochlorothiazide; valsartan5,399,578*PEDSep 21, 2012
LUMIGANAllerganbimatoprost6,403,649Sep 21, 2012
SYMBICORTAstrazenecabudesonide; formoterol fumarate dihydrate6,641,800Sep 23, 2012
DETROL LAPharmacia And Upjohntolterodine tartrate5,382,600*PEDSep 25, 2012
TIKOSYNPfizerdofetilide4,959,366Sep 25, 2012
DETROLPharmacia And Upjohntolterodine tartrate5,382,600*PEDSep 25, 2012
NIMBEX PRESERVATIVE FREEAbbviecisatracurium besylate5,453,510Sep 26, 2012
NIMBEXAbbviecisatracurium besylate5,453,510Sep 26, 2012
REVATIOPfizersildenafil citrate5,250,534*PEDSep 27, 2012
VIAGRAPfizer Irelandsildenafil citrate5,250,534*PEDSep 27, 2012
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Subscribers have access to valuable datasets, including:

  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.